Sunday, February 14, 2021

Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug according to the results from a phase 3 clinical trial.

from Latest Science News -- ScienceDaily https://ift.tt/2Zjxsqe
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Study finds untreated sleep apnea doubles Parkinson’s risk

A massive veteran study found a strong connection between untreated sleep apnea and a higher chance of Parkinson’s. CPAP users had much lowe...